Cytogen Inc

217330 · KQ · Healthcare / Diagnostics & Research

2,320.00KRW+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close2,320.00

Open2,370.00

Day Range2,290.00 – 2,390.00

52-Week Range2,720.00 – 11,200.00

Volume28.85K

Market Cap74.93B

P/E (TTM)0.00

Forward P/E0.00

Dividend Yield0.00%

Beta0.26

50-Day Avg3,182.40

200-Day Avg4,837.80

About

Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained with anti-EpCAM, -CD45, and CK antibodies. The company sells its products under the Smart Biopsy brand name. Cytogen, Inc. was founded in 2010 and is headquartered in Seoul, South Korea.

Company Details

SectorHealthcare
IndustryDiagnostics & Research
CEOMr. Byung-Hee Jeon
Employees42
HeadquartersSK V1 GL Metrocity, Seoul, South Korea, 05854, Korea
Websitehttps://www.cytogenlab.com

Leadership

Mr. Byung-Hee JeonCEO & Director · b. 1959

Financials

Income Statement

Currency: KRW	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	359.68M	489.66M	849.83M	205.87M	1.23B	798.92M	642.67M	347.85M	760.78M	3.18B	10.91B	26.05B
Growth (%)	-	+36.14%	+73.56%	-75.77%	+495.26%	-34.81%	-19.56%	-45.87%	+118.71%	+318.57%	+242.63%	+138.80%
Cost of Revenue	337.12M	426.85M	586.90M	179.49M	913.33M	985.63M	772.30M	290.57M	565.59M	2.34B	8.08B	20.44B
Gross Profit	22.56M	62.81M	262.94M	26.38M	312.15M	-186.70M	-129.63M	57.28M	195.19M	846.22M	2.83B	5.61B
Gross Margin	6.27%	12.83%	30.94%	12.81%	25.47%	-23.37%	-20.17%	16.47%	25.66%	26.57%	25.93%	21.55%
Operating Expense	2.00B	3.19B	2.87B	2.30B	2.94B	4.30B	6.46B	12.92B	11.50B	14.83B	16.86B	13.09B
Operating Income	-1.98B	-3.13B	-2.61B	-2.28B	-2.63B	-4.49B	-6.59B	-12.86B	-11.31B	-13.99B	-14.03B	-7.48B
Operating Margin	-549.25%	-639.30%	-306.77%	-1106.27%	-214.58%	-561.78%	-1024.92%	-3696.55%	-1486.24%	-439.24%	-128.63%	-28.71%
EBITDA	-	-	-	-	-	-	-	-	-13.45B	-11.23B	-13.75B	-7.44B
EBITDA Margin	-	-	-	-	-	-	-	-	-1768.27%	-352.69%	-126.04%	-28.57%
Net Income	-1.37B	-3.81B	-2.15B	-2.62B	-2.60B	-4.14B	-4.89B	-10.87B	-18.77B	-15.77B	-17.12B	-12.34B
Net Income Margin	-381.75%	-777.99%	-252.89%	-1272.69%	-212.09%	-518.30%	-760.70%	-3125.13%	-2467.37%	-495.22%	-156.88%	-47.37%
R&D	540.49M	497.89M	512.73M	98.07M	180.67M	1.23B	1.74B	3.32B	3.20B	3.12B	2.84B	1.89B
R&D as % of Total Revenue	150.27%	101.68%	60.33%	47.64%	14.74%	153.84%	270.48%	953.08%	420.35%	97.89%	26.03%	7.24%
Interest Expense	0	0	0	0	0	0	222.00M	2.66B	3.93B	3.04B	2.09B	2.33B
Interest Expense % of Total Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	34.54%	763.68%	515.97%	95.36%	19.17%	8.96%

Balance Sheet

Currency: KRW	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	2.05B	4.26B	5.06B	5.68B	22.75B	19.72B	28.31B	55.53B	41.22B	74.45B	72.48B	62.24B
Total Liabilities	1.57B	1.60B	4.59B	947.50M	711.51M	1.80B	9.97B	32.52B	35.56B	21.09B	23.89B	26.25B
Total Equity	484.59M	2.66B	475.51M	4.73B	22.04B	17.92B	18.34B	23.01B	5.66B	53.36B	48.58B	35.56B
Cash	404.71M	2.41B	2.80B	4.40B	2.09B	10.07B	11.08B	30.29B	595.73K	54.84B	31.20B	10.99B
Total Debt	-	-	2.31B	-	-	458.91M	5.51B	-	-	-	-	-
Net Debt	-	-	-	-	-	-	-	-	9.88B	-	-	4.50B

Cash Flow

Currency: KRW	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-1.03B	-2.03B	-2.36B	-2.18B	-2.77B	-3.37B	-4.47B	-5.23B	-6.38B	-7.59B	-9.53B	-6.95B
Investing Cash Flow	-539.66M	-294.71M	-232.39M	305.77M	-19.13B	11.68B	-4.09B	-5.58B	-6.65B	263.39M	-24.35B	-
Financing Cash Flow	1.90B	4.33B	2.98B	3.48B	19.59B	-343.09M	9.64B	30.03B	-1.04B	46.24B	9.17B	-
Capital Expenditure	555.59M	354.07M	347.29M	314.82M	1.31B	559.82M	269.69M	2.00B	745.05M	2.62B	1.12B	2.04B
Free Cash Flow	-	-	-	-	-	-	-4.92B	-7.23B	-7.12B	-10.22B	-10.65B	-8.99B
FCF to OCF	-	-	-	-	-	-	110.08%	138.18%	111.68%	134.53%	111.79%	129.30%

Earnings

Report Date	Dec 31, 2018	Mar 31, 2019	Jun 30, 2019	Sep 30, 2019	Dec 31, 2019	Mar 31, 2020	Jun 30, 2020	Sep 30, 2020	Dec 31, 2020	Mar 31, 2021	Jun 30, 2021	Sep 30, 2021	Dec 31, 2021	Mar 31, 2022	Jun 30, 2022	Sep 30, 2022	Dec 31, 2022	Mar 31, 2023	Jun 30, 2023	Sep 30, 2023	Feb 21, 2024	Mar 31, 2024	Jun 30, 2024	Sep 30, 2024	Dec 31, 2024	Mar 31, 2025	Jun 30, 2025	Sep 30, 2025	Dec 31, 2025	Mar 31, 2026	Jun 30, 2026
EPS Estimate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS Actual	-58.24	-50.78	-53.40	-42.11	-98.71	-73.47	-80.43	-90.04	-45.31	-85.01	-6.56	-180.11	-369.63	-123.00	-346.48	-149.46	-443.43	-220.70	-103.87	-149.45	-325.21	-131.87	-132.12	-127.11	-361.73	-105.37	-122.83	-70.30	-236.54	-55.01	-95.01
Surprise	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Timing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Pre-market	-	-	-	-	-	-	-	-	-	-

Key Statistics & Ratios

Market Cap74.93B

Enterprise Value61.81B

Trailing P/E0.00

Forward P/E0.00

Price / Sales2.74

Price / Book2.09

Revenue (TTM)27.38B

Gross Profit (TTM)6.69B

EBITDA-3.78B

Profit Margin-38.52%

Operating Margin-17.80%

Return on Equity-27.40%

Return on Assets-6.66%

Shares Outstanding23.13M

Shares Float11.84M

Beta0.26

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Stock Splits

Sep 28, 2022959692:319897